On Nov 22, major Wall Street analysts update their ratings for $Sage Therapeutics (SAGE.US)$, with price targets ranging from $8 to $14.
TD Cowen analyst Ritu Baral maintains with a hold rating, and maintains the target price at $9.
Oppenheimer analyst Jay Olson maintains with a hold rating, and adjusts the target price from $17 to $8.
Truist Financial analyst Joon Lee maintains with a hold rating.
Scotiabank analyst George Farmer maintains with a buy rating, and maintains the target price at $14.
Furthermore, according to the comprehensive report, the opinions of $Sage Therapeutics (SAGE.US)$'s main analysts recently are as follows:
Following the announcement that the phase 2 DIMENSION trial evaluating dalzanemdor in cognitive impairment associated with Huntington's disease failed to achieve the primary endpoint, the value assigned to this pipeline has been adjusted by removing $75M. The company has emphasized other assets in the early-stage pipeline; however, it is noted that significant clinical validation will be required before additional value can be attributed to these assets.
Sage Therapeutics announced that dalzanemdor did not meet the primary endpoint of change from baseline on the Symbol Digit Modalities Test at day 84 in the Phase 2 Huntington's cognitive impairment study. No statistically significant or clinically meaningful differences were observed on secondary endpoints.
Here are the latest investment ratings and price targets for $Sage Therapeutics (SAGE.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月22日，多家華爾街大行更新了$Sage Therapeutics (SAGE.US)$的評級，目標價介於8美元至14美元。
TD Cowen分析師Ritu Baral維持持有評級，維持目標價9美元。
奧本海默控股分析師Jay Olson維持持有評級，並將目標價從17美元下調至8美元。
儲億銀行分析師Joon Lee維持持有評級。
豐業銀行分析師George Farmer維持買入評級，維持目標價14美元。
此外，綜合報道，$Sage Therapeutics (SAGE.US)$近期主要分析師觀點如下：
在宣佈評估dalzanemdor用於亨廷頓舞蹈症相關認知障礙的第二階段DIMENSION試驗未能達到主要終點後，該管線的價值被調整，減少了7500萬美元。公司強調了早期管線中的其他資產；然而，需要進行重大臨床驗證，才能在這些資產上加上額外的價值。
sage therapeutics宣佈，在第二階段亨廷頓認知障礙研究中，dalzanemdor未能達到基線變化的主要終點，即在第84天的符號數字模態測試中。未觀察到次要終點在統計學上顯著或臨床上有意義的差異。
以下爲今日4位分析師對$Sage Therapeutics (SAGE.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
